BNET Industries

Cangene Corp.

CNJ is in the Pharma Industry

Last Fiscal Year Sales:$98.8M
  • Public
  • CA
Dow Jones Description

Cangene is one of Canada's largest and earliest biopharmaceutical companies. It was founded in 1984 and is headquartered in Winnipeg, Manitoba. Cangene has approximately 650 employees in eight locations across North America. It operates three large manufacturing facilities - two in Winnipeg, Manitoba and one in Baltimore, Maryland - where it produces its own products and undertakes contract manufacturing for a number of companies. Cangene operates three U.S. and one Canadian plasma-collection facilities. In addition, it has a regulatory affairs, sales and investor relations office in Toronto, Ontario.

President, CEO & Director
John Langstaff
Number of Employees 700
Contact Information

155 Innovation Dr

Winnipeg, Manitoba

www.cangene.com

(905) 405-2900

NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414

Recent Events

  • Canadian Stocks May Struggle To Extend Gains

    12/15/09 - Financial Announcement - View Story

  • Cangene books best-ever annual profit, gets a boost from U.S. contracts

    10/22/09 - Financial Announcement - View Story

  • Cangene acquires U.S. commercialization rights for HepaGam BR from Apotex

    10/19/09 - Joint Venture / Alliance - View Story

  • Sparta Systems' TrackWiseR Solution Delivers Workforce Training and Learning Initiatives for Cange

    7/13/09 - Licensing / Contract - View Story

  • Cangene Corporation (CC:CNJ) Acquires Twinstrand Therapeutics

    7/08/09 - Merger / Acquisition - View Story

News & Analysis

cangene corp. - All News and Analysis

  • Cangene Completes Mrp For Winrho Sdf Approval In 10 Countries

    - 2005-02-01

    Cangene has successfully completed the European Mutual Recognition Procedure ("MRP") for the approval of WinRhoRSDF in ten European countries for use in preventing hemolytic disease of the newborn and treating ITP, a clotting disorder. As a result, launch of WinRhoRSDF in the ten countries - Belgium, Finland, Greece, Iceland, Ireland,...

    Tags: Cangene Corp.

  • CANGENE REPORTS EARNINGS OF 52 CENTS PER SHARE FOR FISCAL 2004.

    - 2004-11-01

    Cangene Corporation, Toronto, has reported results for the year ended July 31, 2004. Revenues for the year were $156.9 million, down $29.3 million or 16% from fiscal 2003. Revenues were impacted by the continued strength of the Canadian dollar and decreased activity at the company's Chesapeake...

    Tags: Cangene Corp.

  • Cangene Corp.: Better treatments

    - 2004-01-01

    [HEADNOTE]Better TreatmentsFounded in 1984, Cangene is one of Canada's largest biotechnology companies. Primary activities include: developing, manufacturing and marketing "antibodies" (proteins produced by white blood cells to destroy 'foreign' proteins in the body) and, "recombinant DNA technology" for studying genes. The Apotex Group, one of Canada's largest privately owned pharmaceutical...

    Tags: Cangene Corp.

  • CANGENE CORP.

    - 2004-01-01

    Better TreatmentsFounded in 1984, Cangene is one of Canada's largest biotechnology companies. Primary activities include: developing, manufacturing and marketing "antibodies" (proteins produced by white blood cells to destroy 'foreign' proteins in the body) and, "recombinant DNA technology" for studying genes. The Apotex Group, one of Canada's largest privately owned pharmaceutical...

    Tags: Cangene Corp.

  • Cangene.

    - 2003-01-27

    M2 PRESSWIRE-27 January 2003-Research and Markets: CangeneC1994-2003 M2 COMMUNICATIONS LTD RDATE:01232003 This company profile for Cangene is taken directly from the BiotechWatch database. The BiotechWatch database is a continuously updated interactive database that follows such parameters as products...

    Tags: Cangene Corp.

Decision Makers

Name (plus bio) Position
John Langstaff President, CEO & Director
Michael Graham CFO
Andrew D. Storey Vice President, Quality Assurance & Clinical & Regulatory Affairs
Grant McClarty Vice President, R & D
John W. McMillan Vice President, Commercial Development
Wendy Johnson Vice President, Res & Development
William Labossiere Bees Vice President, Operations
David Young Manager, Contract Manufacturing
Jean Compton Manager, Investor Relations

Board of Directors

Name (plus bio) Position
Bernard C. Sherman Chairman
Craig Baxter Board of Directors
J. Robert Lavery Board of Directors
Jack M. Kay Board of Directors
Jerry Treppel Board of Directors
Michael Spino Board of Directors

Organization Position Status
Cangene Corporation President, CEO & Director Current
Cangene Corporation Board of Directors Current

Organization Position Status
Cangene Corporation CFO Current

Organization Position Status
Cangene Corporation Vice President, Quality Assurance & Clinical & Regulatory Affairs Current

Organization Position Status
Cangene Corporation Vice President, R & D Current

Organization Position Status
Cangene Corporation Vice President, Commercial Development Current

Organization Position Status
Cangene Corporation Vice President, Res & Development Current

Organization Position Status
Cangene Corporation Vice President, Operations Current

Organization Position Status
Cangene Corporation Manager, Contract Manufacturing Current

Organization Position Status
Cangene Corporation Manager, Investor Relations Current

Organization Position Status
Cangene Corporation Chairman Current
Cangene Corporation Board of Directors Current

Organization Position Status
Cangene Corporation Board of Directors Current

Organization Position Status
Cangene Corporation Board of Directors Current

Organization Position Status
Cangene Corporation Board of Directors Current

Organization Position Status
Cangene Corporation Board of Directors Current

Organization Position Status
Cangene Corporation Board of Directors Current
advertisement
IndustryTop Rated

Brought to you by CBS MoneyWatch.com

advertisement
Presented by American Express